Treatment of patients with herpetic infection on the principles of evidence-based medicine
DOI:
https://doi.org/10.14739/2310-1210.2020.3.204958Keywords:
herpes simplex virus infection, drug therapy, evidence-based medicineAbstract
The article summarizes modern approaches to the treatment of patients with herpetic infection based on the principles of evidence-based medicine. The use of technologies and drugs in daily medical practice with proved effectiveness is the main objective of such treatment. The effectiveness of various therapeutic approaches, scientifically based principles of the treatment for patients with this pathology has been analyzed. Combined therapy of herpetic infection should be active, long and include several stages. It is important to take into account the sensitivity of different types of herpes viruses to etiotropic agents and the patient's immune response. Reducing the active replication of the virus, minimizing the likelihood of active virions transmission to the regional ganglia through the use of antiviral therapy, reduction of toxicity, elimination of additional antigenic loads are the main objectives of this treatment. Antiviral drugs - acyclovir and its analogues are used at the first stage. Prolonged intake of acyclovir in suppressive doses within 2–12 months, depending on the disease severity is initiated at the second stage of the treatment. It is also advisable to use immunotherapeutic agents, in particular, preparations of immunoglobulins, recombinant interferons, interferon inducers, while their effectiveness requires further study in modern conditions.
Conclusions. Acyclic nucleoside analogues remain one of the important components of modern treatment for patients with herpetic infection. Randomized studies have shown that three antiviral drugs (acyclovir, valacyclovir and famciclovir) are clinically effective. Systemic antiviral drugs partially control the symptoms of genital herpes in primary and recurrent episodes, and are effective as suppressive therapy. Considering the chronic recurrent nature of this infection, its complications and consequences, the combined use of replacement immunotherapy with etiotropic antiviral drugs is possible.
References
Ministry of Health of Ukraine. (2016, December 29). Pro vnesennia zmin do nakazu Ministerstva okhorony zdorovia Ukrainy vid 28 veresnia 2012 roku № 751 [On Changes to the Order of the Ministry of Health of Ukraine dated September 28, 2012 No. 751 (No. 1422)]. https://zakon.rada.gov.ua/laws/show/z0530-17
Ministry of Health of Ukraine. (2017, December 19). Yak vprovadzhuvaty novi klinichni protokoly: instruktsiia dlia likariv 1/4 [How to implement new clinical protocols: instructions for doctors 1/4]. MOZ Ukrainy. http://moz.gov.ua/article/for-medical-staff/jak-vprovadzhuvati-novi-klinichni-protokoli-instrukcija-dlja-likariv
Duda, O. K., Krasnov, M. I., & Kozko, V. M. (2015). Herpetychna ta herpesvirusna infektsiia [Herpetic and herpesvirus infection]. NMAPO. [in Ukrainian].
Holubovska, O. A. (Ed.). (2012). Infektsiini khvoroby [Infectious diseases]. VSV "Medytsyna". [in Ukrainian].
Sen, P., & Barton, S. E. (2007). Genital herpes and its management. BMJ, 334(7602), 1048-1052. https://doi.org/10.1136/bmj.39189.504306.55
Genital HSV Infections. (2015) Centers for Disease Control and Prevention. https://www.cdc.gov/std/tg2015/herpes.htm
Committee on Infectious Diseases, American Academy of Pediatrics, Kimberlin, D. W., Brady, M. T., Jackson, M. A., & Long, S. S.(Eds.). (2018). Red Book: 2018-2021 Report of the Committee on Infectious Diseases (31st ed.). American Academy of Pediatrics.
World Health Organization. (2016). WHO Guidelines for the Treatment of Genital Herpes Simplex Virus. WHO Press. https://www.who.int/reproductivehealth/publications/rtis/genital-HSV-treatment-guidelines/en/
Patel, R., Kennedy, O. J., Clarke, E., Geretti, A., Nilsen, A., Lautenschlager, S., Green, J., Donders, G., van der Meijden, W., Gomberg, M., Moi, H., & Foley, E. (2017). 2017 European guidelines for the management of genital herpes. International journal of STD & AIDS, 28(14), 1366-1379. https://doi.org/10.1177/0956462417727194
Patel, R., Green, J., Clarke, E., Seneviratne, K., Abbt, N., Evans, C., Bickford, J., Nicholson, M., O'Farrell, N., Barton, S., FitzGerald, M., & Foley, E. (2015). 2014 UK national guideline for the management of anogenital herpes. International journal of STD & AIDS, 26(11), 763-776. https://doi.org/10.1177/0956462415580512
Royal College of Obstetricians & Gynaecologists. (2014, October 17). Management of Genital Herpes in Pregnancy. RCOG. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/genital-herpes/
American College of Obstetricians and Gynecologists Committee on Practice Bulletins. (2007). ACOG Practice Bulletin No. 82: Management of Herpes in Pregnancy. Obstetrics & Gynecology, 109(6), 1489-1498. https://doi.org/10.1097/01.aog.0000263902.31953.3e
Australasian Sexual Health Alliance. (2018, March 29). Herpes. Australian STI Management Guidelines. http://www.sti.guidelines.org.au/sexually-transmissible-infections/herpes
Aoki, F. Y., Tyring, S., Diaz-Mitoma, F., Gross, G., Gao, J., & Hamed, K. (2006). Single-Day, Patient-Initiated Famciclovir Therapy for Recurrent Genital Herpes: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 42(1), 8-13. https://doi.org/10.1086/498521
Bodsworth, N. J., Crooks, R. J., Borelli, S., Vejlsgaard, G., Paavonen, J., Worm, A. M., Uexkull, N., Esmann, J., Strand, A., Ingamells, A. J., & Gibb, A. (1997). Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourinary medicine, 73(2), 110-116. https://doi.org/10.1136/sti.73.2.110
Fife, K. H., Barbarash, R. A., Rudolph, T., Degregorio, B., & Roth, R. (1997). Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sexually transmitted diseases, 24(8), 481-486. https://doi.org/10.1097/00007435-199709000-00007
Reyes, M., Shaik, N. S., Graber, J. M., Nisenbaum, R., Wetherall, N. T., Fukuda, K., Reeves, W. C., & Task Force on Herpes Simplex Virus Resistance. (2003). Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Archives of internal medicine, 163(1), 76-80. https://doi.org/10.1001/archinte.163.1.76
Safrin, S., Crumpacker, C., Chatis, P., Davis, R., Hafner, R., Rush, J., Kessler, H. A., Landry, B., & Mills, J. (1991). A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. The New England journal of medicine, 325(8), 551-555. https://doi.org/10.1056/NEJM199108223250805
Perkins, N., Nisbet, M., & Thomas, M. (2011). Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review. Sexually transmitted infections, 87(4), 292-295. https://doi.org/10.1136/sti.2010.047431
Scott, L. L., Hollier, L. M., McIntire, D., Sanchez, P. J., Jackson, G. L., & Wendel, G. D. Jr. (2002). Acyclovir suppression to prevent recurrent genital herpes at delivery. Infectious diseases in obstetrics and gynecology, 10(2), 71-77. https://doi.org/10.1155/S1064744902000054
Pinninti, S. G., Angara, R., Feja, K. N., Kimberlin, D. W., Leach, C. T., Conrad, D. A., McCarthy, C. A., & Tolan, R. W. Jr. (2012). Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. The Journal of pediatrics, 161(1), 134-138.e3. https://doi.org/10.1016/j.jpeds.2011.12.053
Momper, J. D., Mulugeta, Y., Green, D. J., Karesh, A., Krudys, K. M., Sachs, H. C., Yao, L. P., & Burckart, G. J. (2013). Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA pediatrics, 167(10), 926-932. https://doi.org/10.1001/jamapediatrics.2013.465
Acyclovir and Valacyclovir Pregnancy Registries. (n.d.). GSK Pregnancy Registries. http://pregnancyregistry.gsk.com/acyclovir.html
Andrews, W. W., Kimberlin, D. F., Whitley, R., Cliver, S., Ramsey, P. S., & Deeter, R. (2006). Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. American journal of obstetrics and gynecology, 194(3), 774-781. https://doi.org/10.1016/j.ajog.2005.11.051
Hollier, L. M., & Wendel, G. D. (2008). Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database of Systematic Reviews, (1), Article CD004946. https://doi.org/10.1002/14651858.CD004946.pub2
Hemelaar, S., Poeran, J., Steegers, E., & van der Meijden, W. (2014). Neonatal herpes infections in The Netherlands in the period 2006-2011. The Journal Of Maternal-Fetal & Neonatal Medicine, 28(8), 905-909. https://doi.org/10.3109/14767058.2014.937691
Le Cleach, L., Trinquart, L., Do, G., Maruani, A., Lebrun-Vignes, B., Ravaud, P., & Chosidow, O. (2014). Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database of Systematic Reviews, (8), Article CD009036. https://doi.org/10.1002/14651858.cd009036.pub2
Heslop, R., Roberts, H., Flower, D., & Jordan, V. (2016). Interventions for men and women with their first episode of genital herpes. Cochrane Database of Systematic Reviews, (8), Article CD010684. https://doi.org/10.1002/14651858.CD010684.pub2
Wilhelmus, K. R. (2015). Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database of Systematic Reviews, (1), Article CD002898. https://doi.org/10.1002/14651858.CD002898.pub5
Sperling, I. A., Vengerovskii, A. I., & Sperling, N. V. (2010). Farmakologicheskaya korrektsiya induktorami interferona tsitokinovykh narushenii pri retsidiviruyushchem genital'nom gerpese [Use of interferon inducers for pharmacological correction of cytokine disturbances in patients with recurrent genital herpes]. Eksperimental'naya i klinicheskaya farmakologiya, 73(8), 39-42. https://doi.org/10.30906/0869-2092-2010-73-8-39-42 [in Russian].
Kopcha, V. S., Lipkovska, I. V., & Shpikula, N. H. (2018). Profilaktyka reaktyvatsii herpesvirusnykh infektsii pered planovanoiu vahitnistiu [Prophylaxis of herpetic infections reactivation before the planned pregnancy]. Zaporozhye medical journal, 20(4), 529-537. https://doi.org/10.14739/2310-1210.2018.4.135804 [in Ukrainian].
Mouthon, L., & Lortholary, O. (2003). Intravenous immunoglobulins in infectious diseases: where do we stand? Clinical Microbiology and Infection, 9(5), 333-338. https://doi.org/10.1046/j.1469-0691.2003.00694.x
Laupland, K. B., Boucher, P., Rotstein, C., Cook, D. J., & Doig, C. J. (2004). Intravenous immunoglobulin for severe infections: a survey of Canadian specialists. Journal of Critical Care, 19(2), 75-81. https://doi.org/10.1016/j.jcrc.2004.04.001
Ferrara, G., Zumla, A., & Maeurer, M. (2012). Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections. The American Journal of Medicine, 125(10), Article 1036.e1-1036.e8. https://doi.org/10.1016/j.amjmed.2012.01.023
Vepryk, T. V. (2013). Efektyvnist imunohlobulinoterapii u likuvanni VIL-infikovanykh z aktyvnymy formamy herpetychnoi infektsii [Efficiency of Imunoglobulin Therapy in Treatment of HIVInfected Patients with Active Forms of Herpetic Infection]. Halytskyi likarskyi visnyk, 20(2), 29-31. [in Ukrainian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
